ProCE Banner Activity

CE / CME

XDROs in Complex Clinical Infections: An Advanced Course on the Hardest-to-Treat Cases

Multimedia

In this on-demand webcast, learn from experts about infections caused by gram-negative extensively drug-resistant organisms (XDROs), including epidemiology associated with antimicrobial resistance and approaches to selecting treatment regimens based on the latest data, patient-specific factors, and pharmacokinetic/pharmacodynamic considerations through challenging clinical cases.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: February 03, 2023

Expiration: February 02, 2024

No longer available for credit.

Share

Faculty

Yohei Doi

Yohei Doi, MD, PhD

Professor of Medicine
Division of Infectious Diseases
University of Pittsburgh School of Medicine
Infectious Diseases Specialist
Division of Infectious Diseases
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Emily Heil

Emily Heil, PharmD, MS, BCIDP, AAHIVP

Associate Professor
Department of Practice, Sciences, and Health Outcomes Research
University of Maryland School of Pharmacy
Infectious Diseases Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Shionogi Inc

Target Audience

This program is intended for physicians (eg, critical care/pulmonologist, infectious disease, internal medicine/hospitalist), pharmacists (critical care, infectious disease), nurses, and other healthcare professionals (eg, NPs/PAs, microbiologists) who provide care for patients with antimicrobial resistant gram-negative infections.

Program Learning Goal

The goal of this activity is to improve participants’ competence in selecting appropriate antibiotic regimens for empiric or targeted treatment of complex clinical infections caused by antimicrobial resistant gram-negative pathogens.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate clinically relevant extensively drug-resistant gram-negative organisms (XDROs) including epidemiology, mechanisms of antimicrobial resistance, and virulence factors

  • Compare novel antimicrobial treatment options for patients with antimicrobial-resistant gram-negative infections, including pharmacokinetics/pharmacodynamics and activity in the setting of key resistance mechanisms

  • Apply the latest data and suggested approaches for selection of optimized treatment regimens targeting XDROs in patients with complex clinical infections

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Yohei Doi, MD, PhD: consultant/advisor/speaker: bioMérieux, Chugai, Fujifilm, Gilead Sciences, GlaxoSmithKline, Meiji Seika Pharma, Moderna, MSD, Shinogi; researcher: Entasis.

Emily Heil, PharmD, MS, BCIDP, AAHIVP, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 03, 2023, through February 02, 2024:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 

Physician Continuing Medical Education Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education


Credit Designation CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-048-H01-P. 
Type of Activity: Application

Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.